Organization
Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland
1 abstract
Abstract
Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).Org: Clinica São Germano, São Paulo, Brazil, Medical University of Lodz, Lodz, Poland, Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland, The First Affiliated Hospital of Soochow University, Suzhou, China, Gorodskaya Klinicheskaya Bol'nitsa Im. Botkina, Moscow, Russian Federation,